Ganoderma lucidum Protects Dopaminergic Neuron Degeneration
Author Information
Author(s): Zhang Ruiping, Xu Shengli, Cai Yanning, Zhou Ming, Zuo Xiaohong, Chan Piu
Primary Institution: Beijing Institute of Geriatrics and Department of Neurobiology and Neurology, Key Laboratory for Neurodegenerative Diseases of Ministry of Education, Xuanwu Hospital of Capital Medical University
Hypothesis
Ganoderma lucidum may possess potent anti-inflammatory and immunomodulating properties that protect dopaminergic neurons from degeneration.
Conclusion
Ganoderma lucidum may be a promising agent for the treatment of Parkinson's disease through its anti-inflammatory effects.
Supporting Evidence
- Ganoderma lucidum extracts significantly prevent the production of microglia-derived proinflammatory and cytotoxic factors in a dose-dependent manner.
- GL pretreatment reduced the levels of TNF-α and IL-1β after exposure to inflammatory stimuli.
- GL protected dopaminergic neurons from MPP+-induced neurodegeneration.
- GL inhibited the increased expression of TNF-α and IL-1β mRNA by LPS and MPP+-treated membranes.
Takeaway
Ganoderma lucidum, a type of mushroom, can help protect brain cells from damage caused by inflammation, which is important for people with Parkinson's disease.
Methodology
The study used co-cultures of dopaminergic neurons and microglia to assess the effects of Ganoderma lucidum extracts on microglial activation and neuroinflammation.
Statistical Information
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website